KEYTRUDA

KEYTRUDA

Displaying 10 out of 9 results

  1. The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

    Merck's Keytruda fails late-stage study in liver cancer patients

    Merck & Co Inc said on Tuesday its cancer drug Keytruda failed the main goals of a late-stage trial and did not extend life of patients with a ...
  2. A logo of American pharmaceutical corporation Pfizer Inc., is pictured in Toluca

    Merck, Pfizer drug combo extends kidney cancer survival: study

    A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those ...
  3. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

    Merck to further study Keytruda in prostate cancer after early success

    Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for ...
  4. A view of the Merck & Co. campus in Linden, New Jersey

    Merck raised prices five drugs including Keytruda in November

    Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including ...
  5. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

    Merck drug Keytruda succeeds in late-stage esophageal cancer trial

    U.S. drugmaker Merck & Co said on Wednesday its blockbuster cancer drug Keytruda met the main goal of a late-stage trial, of extending the lives ...
  6. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

    Merck, Pfizer combo treatment meets main goals of kidney cancer trial

    Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study ...
  7. FILE PHOTO:  The logo of Merck is pictured in this illustration photograph in Cardiff

    Merck's Keytruda boosts response in hard-to-treat lung cancer

    The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous ...
  8. NYSE Feb 2

    US stocks end flat ahead of January jobs data

    Wall Street stocks finished little changed on Thursday in cautious trading ahead of key US jobs data.